Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology - United States
doi 10.1001/jamaoncol.2019.0339
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Resource Utilization and Cost Saving Analysis of Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer Patients

Oncotarget
Oncology
2017English

Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

NT-proBNP Correlates With LVEF Decline in HER2-positive Breast Cancer Patients Treated With Trastuzumab

Cardio-Oncology
2019English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory
Cancer ResearchOncology
2017English

Women With Early Breast Cancer to Be Tested for Trastuzumab Treatment

BMJ
2005English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Trastuzumab in Combination With Metronomic Cyclophosphamide and Methotrexate in Patients With HER-2 Positive Metastatic Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2006English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

Oncologist
Cancer ResearchMedicineOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy